in Development by Norvax AS at Norsk Vaksinefabrikk and SINTEF

1. How mRNA Vaccines Work for infectious disease, autoimmune disease, cancer.

2. How mRNA Vaccines will be Manufactured at Norsk Vaksinefabrikk.

3. How mRNA Vaccines are monitored for Safety and Effectiveness.

mRNA Vaccine Production Innovation

As new vaccine development technologies emerge for mRNA and plasmid DNA (pDNA) production processes Norsk Vaksinefabrikk plans to deploy innovative technologies in cooperation with strategic technology vendors to capitalize on the rapid rate of developments and improvements in mRNA Vaccine Production for the benefit of investors, customers and global public health.

mRNA Vaccine Advantages

mRNA Vaccine production is a non-cellular process and therefore has numerous advantages:

  1. The process is simpler.
  2. The process is more robust.
  3. Dose production is faster.
  4. The facilities and equipment can be an order of magnitude smaller.
  5. The capital costs are lower.
  6. The process can be implemented in more existing facilities.
  7. The process can be quickly repurposed for new variants, or even new viral threats.

mRNA Vaccine Materials Innovation

One of the primary components of the mRNA Vaccine is the delivery mechanism known as the lipid nanoparticle to encapsulate the mRNA molecule for safe and effective delivery into the cell. Norsk Vaksinefabrikk by Norvax AS is developing the NORVAX-LNP product in cooperation with SINTEF for inclusion in the mRNA Vaccine Platform by Norsk Vaksinefabrikk.

NORVAX-LNP research and development is supported by The Research Council of Norway Project 327871. Development of a proprietary/licensed lipid nanoparticle (LNP) platform for an mRNA formulation, with SINTEF